Sartorius Stedim Biotech (CHIX:DIMP) LT-Debt-to-Total-Asset: 0.25 (As of Mar. 2026)

What is Sartorius Stedim Biotech LT-Debt-to-Total-Asset?

Sartorius Stedim Biotech CHIX:DIMP 84 LT-Debt-to-Total-Asset is 0.25 as of Mar. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €204.38 (Modestly Undervalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sartorius Stedim Biotech's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.25.

Sartorius Stedim Biotech's long-term debt to total assets ratio declined from Mar. 2025 (0.34) to Mar. 2026 (0.25). It may suggest that Sartorius Stedim Biotech is progressively becoming less dependent on debt to grow their business.

Sartorius Stedim Biotech (CHIX:DIMp) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sartorius Stedim Biotech LT-Debt-to-Total-Asset Related Terms

Sartorius Stedim Biotech LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech LT-Debt-to-Total-Asset Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.15

0.22

0.47

0.34

0.25

Sartorius Stedim Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.34	0.34	0.26	0.25	0.25

84GF Score

Sartorius Stedim Biotech SA CHIX:DIMP

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sartorius Stedim Biotech LT-Debt-to-Total-Asset Calculation

Sartorius Stedim Biotech's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	2018.6	/	7984
	=	0.25

Sartorius Stedim Biotech's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	2008.9	/	8189.8
	=	0.25

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.25 mean?

Sartorius Stedim Biotech (CHIX:DIMP) has a LT-Debt-to-Total-Asset of 0.25 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sartorius Stedim Biotech and its competitors.

Is Sartorius Stedim Biotech's LT-Debt-to-Total-Asset too high?

Sartorius Stedim Biotech's current LT-Debt-to-Total-Asset is 0.25. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Sartorius Stedim Biotech's LT-Debt-to-Total-Asset compare to ISRG and BDX?

Sartorius Stedim Biotech's LT-Debt-to-Total-Asset of 0.25 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current LT-Debt-to-Total-Asset is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sartorius Stedim Biotech stock overvalued right now?

Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €204.38, compared to a current price of €180.90 — trading 11.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.25. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current LT-Debt-to-Total-Asset is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €180.90 is trading 11.5% below its estimated GF Value™ of €204.38. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

LT-Debt-to-Total-Asset: 0.25
GF Value™: €204.38 vs. price of €180.90 (11.5% below fair value)
GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies XPAR:ALCJ XPAR:MLBON XPAR:ALSPW XPAR:ALSAF XPAR:EL ISRG TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543 COO SOLV OCSE:COLO B NZSE:FPH ALGN BAX

Other Exchanges SRTOY:USA SDMHF:USA 0RG8:UK DIM:France 56S1:Germany

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website https://www.sartorius.com

Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.

84GF Score

Get the complete analysis for CHIX:DIMP

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€180.90

Price

€204.38

GF Value

View CHIX:DIMP Analysis

See LT-Debt-to-Total-Asset data for all stocks →